Back to User profile » Dr Matteo Megna

Papers published by Dr Matteo Megna:


The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials

Potestio L, Martora F, Lauletta G, Vallone Y, Battista T, Megna M

Clinical, Cosmetic and Investigational Dermatology 2024, 17:829-842

Published Date: 10 April 2024

The Past, the Present and the Future of Teledermatology: A Narrative Review

Tommasino N, Megna M, Cacciapuoti S, Villani A, Martora F, Ruggiero A, Genco L, Potestio L

Clinical, Cosmetic and Investigational Dermatology 2024, 17:717-723

Published Date: 21 March 2024

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report

Martora F, Battista T, Potestio L, Portarapillo A, Tommasino N, Megna M

Clinical, Cosmetic and Investigational Dermatology 2024, 17:483-487

Published Date: 29 February 2024

L-Lysine as an Alternative Treatment for Pityriasis Rosea (PR) [Response to Letter]

Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A

Clinical, Cosmetic and Investigational Dermatology 2024, 17:463-464

Published Date: 24 February 2024

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio L, Battista T, Scalvenzi M, Megna M

Clinical, Cosmetic and Investigational Dermatology 2024, 17:159-166

Published Date: 23 January 2024

Pityriasis Rosea and Pityriasis Rosea-Like Eruption Following COVID-19 Vaccination: A Narrative Review

Potestio L, Martora F, Cacciapuoti S, Megna M, Villani A, Ruggiero A

Clinical, Cosmetic and Investigational Dermatology 2024, 17:51-57

Published Date: 8 January 2024

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab

Megna M, Ruggiero A, Salsano A, Lauletta G, Portarapillo A, Torta G, Martora F, Potestio L

Clinical, Cosmetic and Investigational Dermatology 2023, 16:3503-3507

Published Date: 5 December 2023

Herpes Zoster and COVID-19 Vaccination: A Narrative Review

Potestio L, Megna M, Villani A, Cacciapuoti S, Scalvenzi M, Martora F

Clinical, Cosmetic and Investigational Dermatology 2023, 16:3323-3331

Published Date: 16 November 2023

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics

Ruggiero A, Portarapillo A, Megna M, Patruno C, Napolitano M

Pediatric Health, Medicine and Therapeutics 2023, 14:435-451

Published Date: 14 November 2023

JAK Inhibitors in Psoriatic Disease

Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L

Clinical, Cosmetic and Investigational Dermatology 2023, 16:3129-3145

Published Date: 31 October 2023

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas

Cacciapuoti S, Potestio L, Guerrasio G, Fabbrocini G, Scalvenzi M, Ruggiero A, Caiazzo G, Megna M

Clinical, Cosmetic and Investigational Dermatology 2023, 16:2637-2644

Published Date: 25 September 2023

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data

Martora F, Scalvenzi M, Battista T, Fornaro L, Potestio L, Ruggiero A, Megna M

Clinical, Cosmetic and Investigational Dermatology 2023, 16:2525-2536

Published Date: 18 September 2023

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, Battista T, Megna M

Clinical, Cosmetic and Investigational Dermatology 2023, 16:2045-2059

Published Date: 4 August 2023

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments

Battista T, Scalvenzi M, Martora F, Potestio L, Megna M

Clinical, Cosmetic and Investigational Dermatology 2023, 16:1899-1932

Published Date: 24 July 2023

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?

Megna M, Camela E, Ruggiero A, Battista T, Martora F, Cacciapuoti S, Potestio L

Clinical, Cosmetic and Investigational Dermatology 2023, 16:1677-1690

Published Date: 28 June 2023

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature

Potestio L, Ruggiero A, Fabbrocini G, Martora F, Megna M

Psoriasis: Targets and Therapy 2023, 13:19-26

Published Date: 4 May 2023

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis

Potestio L, Martora F, Fabbrocini G, Battista T, Megna M

Psoriasis: Targets and Therapy 2023, 13:11-18

Published Date: 12 April 2023

Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study

Matteo M, Battista T, Noto M, Picone V, Fabbrocini G, Ruggiero A, Genco L

Clinical, Cosmetic and Investigational Dermatology 2023, 16:553-564

Published Date: 2 March 2023

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M

Clinical, Cosmetic and Investigational Dermatology 2023, 16:529-536

Published Date: 27 February 2023

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection

Potestio L, Piscitelli I, Fabbrocini G, Martora F, Ruggiero A, Megna M

Clinical, Cosmetic and Investigational Dermatology 2023, 16:369-373

Published Date: 5 February 2023

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience

Martora F, Megna M, Battista T, Potestio L, Annunziata MC, Marasca C, Villani A, Fabbrocini G

Clinical, Cosmetic and Investigational Dermatology 2023, 16:135-148

Published Date: 19 January 2023

Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study

Stingeni L, Malara G, Conti A, Di Costanzo L, Carrera CG, Burlando M, Malagoli P, Musumeci ML, Bardazzi F, Brazzelli V, Amerio P, De Simone C, Trevisini S, Balato A, Megna M, Loconsole F, De Felice C, Bartezaghi M, Rausa A, Aloisi E, Orsenigo R, Costanzo A

Clinical, Cosmetic and Investigational Dermatology 2023, 16:27-38

Published Date: 5 January 2023

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review

Ruggiero A, Martora F, Fabbrocini G, Villani A, Marasca C, Megna M, Fornaro L, Comune R, Potestio L

Clinical, Cosmetic and Investigational Dermatology 2022, 15:2785-2793

Published Date: 19 December 2022

Towards Personalized Medicine in Psoriasis: Current Progress

Camela E, Potestio L, Ruggiero A, Ocampo-Garza SS, Fabbrocini G, Megna M

Psoriasis: Targets and Therapy 2022, 12:231-250

Published Date: 1 September 2022

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence

Ruggiero A, Picone V, Martora F, Fabbrocini G, Megna M

Clinical, Cosmetic and Investigational Dermatology 2022, 15:1649-1658

Published Date: 16 August 2022

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study

Megna M, Potestio L, Fabbrocini G, Ruggiero A

Psoriasis: Targets and Therapy 2022, 12:205-212

Published Date: 14 July 2022

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study

Megna M, Fornaro L, Potestio L, Luciano MA, Nocerino M, Delfino M, Guarino M, Fabbrocini G, Camela E

Psoriasis: Targets and Therapy 2022, 12:199-204

Published Date: 9 July 2022

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge

Ruggiero A, Potestio L, Camela E, Fabbrocini G, Megna M

Psoriasis: Targets and Therapy 2022, 12:127-137

Published Date: 8 June 2022

Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment

Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G, Monfrecola G

Clinical, Cosmetic and Investigational Dermatology 2017, 10:105-115

Published Date: 19 April 2017